SAR245409 (XL765) is primarily investigated for its potential in cancer therapy due to its ability to inhibit key signaling pathways involved in tumor growth and survival. It functions as a dual inhibitor of PI3K and mTOR, two critical proteins in the PI3K/AKT/mTOR pathway, which is often dysregulated in various cancers. By blocking this pathway, the compound can suppress cell proliferation, induce apoptosis, and inhibit angiogenesis.

It has been studied in preclinical models for a range of solid tumors and hematological malignancies, showing activity against breast, lung, and prostate cancers, among others. Its ability to cross the blood-brain barrier also makes it a candidate for treating brain tumors or metastases. Additionally, SAR245409 has been explored for use in combination therapies, where it may enhance the efficacy of chemotherapy, targeted therapy, or immunotherapy by overcoming resistance mechanisms mediated by PI3K/mTOR signaling.